OrthoPediatrics Q4 EBITDA misses estimates

Orthopediatrics

26/02/2026 21:45

Overview

Pediatric orthopedics firm's Q4 revenue grew 17% yr/yr

Adjusted EBITDA for Q4 missed analyst expectations

Company generated positive free cash flow for first time in Q4

Outlook

OrthoPediatrics expects 2026 revenue between $262 mln and $266 mln

Company anticipates 2026 adjusted EBITDA of $25 mln

OrthoPediatrics projects breakeven free cash flow in 2026

Result Drivers

TRAUMA AND DEFORMITY GROWTH - Q4 revenue growth driven by expansion in Trauma and Deformity segments, supported by Pega products and Ex-Fix

INTERNATIONAL REVENUE SURGE - International revenue increased 33% in Q4, contributing significantly to overall revenue growth

Company press release: ID:nGNX4bht1v

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.43
Q4 Net Income
-$10.10 mln
Q4 Adjusted EBITDA
Miss
$4.80 mln
$6.18 mln (8 Analysts)
Q4 Gross Margin
73.20%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $23.00, about 37.6% above its February 25 closing price of $16.72

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)